HomeInsightsStock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Ipca Laboratories Ltd Stock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Ipca Laboratories Ltd Stock Comparison

Last Updated on: May 05, 2025

Key Highlights

  • The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2913 as of 05 May 10:47.
  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 226.4 on March 2020 to 55.8 on March 2024 . This represents a CAGR of -24.43% over 5 yearsThe P/E Ratio of Ipca Laboratories Ltd changed from 28.9 on March 2020 to 57.4 on March 2024 . This represents a CAGR of 14.71% over 5 years.
  • The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 21095 crore on March 2020 to ₹ 32917 crore on March 2024 . This represents a CAGR of 9.31% over 5 yearsThe Market Cap of Ipca Laboratories Ltd changed from ₹ 17538 crore on March 2020 to ₹ 31414 crore on March 2024 . This represents a CAGR of 12.36% over 5 years.
  • The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '24 is ₹ 984.49 crore as compare to the Sep '24 revenue of ₹ 1050 crore. This represent the decline of -6.24% The revenue of Ipca Laboratories Ltd for the Dec '24 is ₹ 2265 crore as compare to the Sep '24 revenue of ₹ 2381 crore. This represent the decline of -4.86%.
  • The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '24 is ₹ 326.99 crore as compare to the Sep '24 ebitda of ₹ 360.94 crore. This represent the decline of -9.41% The ebitda of Ipca Laboratories Ltd for the Dec '24 is ₹ 483.19 crore as compare to the Sep '24 ebitda of ₹ 467.74 crore. This represent the growth of 3.3%.
  • The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 132.25 crore to ₹ 229.88 crore over 7 quarters. This represents a CAGR of 37.15% The net profit of Ipca Laboratories Ltd changed from ₹ 166.21 crore to ₹ 277.33 crore over 7 quarters. This represents a CAGR of 33.98% .
  • The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 615.76 % on March 2020 to 92.72 % on March 2024 . This represents a CAGR of -31.52% over 5 yearsThe Dividend Payout of Ipca Laboratories Ltd changed from 9.68 % on March 2020 to 19.13 % on March 2024 . This represents a CAGR of 14.60% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. The Company's portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease.
  • Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases.

About Ipca Laboratories Ltd

  • Ipca Laboratories Limited (IPCA) was incorporated on 19th October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
  • The products of the Company are now sold in over 100 countries across the globe.
  • The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GlaxoSmithKline Pharmaceuticals to conduct board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

19 Apr 2025 09:56

News

Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmala...

Read more

06 Feb 2025 12:00

News

GlaxoSmithKline Pharmaceuticals revises board meeting date

GlaxoSmithKline Pharmaceuticals has revised the meeting of the Board of Directors which wa...

Read more

21 Jan 2025 11:16

News

GlaxoSmithKline Pharmaceuticals declare Quarterly Result

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

15 Jan 2025 15:27

News

GSK Pharma gains as Q2 PAT rises 15% YoY to Rs 249 cr

Profit before exceptional item and tax was at Rs 338.70 crore in the September 2024 quarte...

Read more

30 Oct 2024 10:39

News

Board of GlaxoSmithKline Pharmaceuticals recommends Special Interim Dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

29 Oct 2024 16:10

Ipca Laboratories Ltd News Hub

News

Ipca Laboratories now holds 100% stake in Unichem Laboratories, Ireland

Ipca Laboratories announced that 100% of the paid-up equity share capital of Unichem Labor...

Read more

02 May 2025 11:27

News

Ipca Laboratories appoints President - Human Resources

Ipca Laboratories has appointed Saidutta Nanda as President - Human Resources of the compa...

Read more

03 Mar 2025 16:06

News

Ipca Laboratories Ltd down for fifth straight session

Ipca Laboratories Ltd is down for a fifth straight session today. The stock is quoting at ...

Read more

28 Feb 2025 13:35

News

Ipca Labs spurts after Q3 PAT soars to Rs 267 cr

Revenue from operations jumped 10.34% YoY to Rs 1,662.68 crore in the quarter ended 31st D...

Read more

13 Feb 2025 15:03

News

Ipca Laboratories to announce Quarterly Result

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 Febru...

Read more

27 Jan 2025 14:16

News

Ipca Laboratories Ltd spurts 0.49%, rises for fifth straight session

Ipca Laboratories Ltd gained for a fifth straight session today. The stock is quoting at R...

Read more

01 Jan 2025 13:00

SWOT Analysis Of Ipca Laboratories Ltd

Strength

2

S

Weakness

4

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Ipca Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Ipca Laboratories Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Ipca Laboratories Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 48,322 Cr while Market cap of Ipca Laboratories Ltd is 34,971 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Ipca Laboratories Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Ipca Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Ipca Laboratories Ltd?

As of May 5, 2025, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2852.45. On the other hand, Ipca Laboratories Ltd stock price is INR ₹1378.45.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Ipca Laboratories Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Ipca Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions